Identification of therapy options for Rare and Resistant Gastrointestinal Stromal Tumors (GIST)


1Rebecca Feldman, PhD, 1Sandeep Reddy, MD, 1Zoran Gatalica, MD DSc, 2Michael J. Pishvaian, MD PhD

Background: GISTs are predominantly defined by KIT/PDGFRA mutations which are targetable with a range of kinase inhibitors, however the majority become TKI-resistant (TKI-R). Double (KIT/PDGFRA) wildtype (D-WT) GISTs represent a rare subset of GIST patients in need of treatment options. We investigated a commercial database of theranostic biomarkers for the identification of novel therapy options for GIST.

Download Publication